Pharmacovigilance translations must be done carefully, as the accuracy of translated documents has a direct impact on information evaluation and patient health and well-being. However, with volumes of non-English source documents increasing, the speed at which these translations are completed is also crucial, as any delays in communication can lead to serious consequences, such as harm to patients, legal liability, and missed regulatory deadlines for adverse event reporting.

“Modern agencies today need to be consultants first, leaning away from manual work and toward strategic consultative contributions,” explained Chief Technology Officer Oleg Korenfeld. “This is only step one for us.  We continue to find opportunities to automate to increase speed in other processes and have our expert teams focus more on strategic council. The new generation of advertising employees – at every level – will have more exciting careers.”

Together the organizations aim to transform pharmaceutical operations and accelerate patient impact.

The integration of AI services including Microsoft’s OpenAI, owner of viral chatbot ChatGPT, will help ease the burden on healthcare staff during virtual exams, Teladoc said.

Organizations continue to recognize the value of the large volumes of data they have collected and their potential for improving the quality, safety, and continuity of care. To utilize the data effectively and appropriately realize these benefits, organizations must overcome the challenges associated with transforming the data for use in healthcare.

Lifesciences firms need to invest in technology that unifies data and workflows across medical information teams and safety teams. Integrating MI and safety helps them optimize the drug development lifecycle and ultimately drive greater patient safety.

Part III: Leaders in healthcare marketing and communications explain where technology will have the most impact on the industry.

Adopting digital transformation is now an industry standard for success – but what precisely does that mean for the clinical development landscape? Gary Shorter, Head of Artificial Intelligence at IQVIA, explores the answers.

As organizations continue to evaluate and implement automation and AI technology, it is important to consider how increased use of technology should align with both industry best practices and regulations – and to proactively address how technology adoption will impact stakeholders involved in routine pharmacovigilance activities while ensuring deployment and implementation poses no risk to breaching guidelines or regulations.